Research
Hormonal
Incretin-based therapies, including GLP-1 receptor agonists like semaglutide and tirzepatide, can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.
Practitioners may consider incretin-based therapies as effective treatment options for improving health outcomes in patients with obesity-related HFpEF.
StrongSupportsmedium confidence
Recent results from randomized clinical trials (RCTs) suggest that incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (e.g., semaglutide) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs (e.g., tirzepatide), can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.
Why this rating
Based on results from randomized clinical trials.
Source
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Thomaz Alexandre Costa et al. · Current Opinion in Cardiology · 2025
reviewCited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →